2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.08 Aumolertinib as Neoadjuvant Therapy for EGFR M+ NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated

EP.08D.08 Aumolertinib as Neoadjuvant Therapy for EGFR M+ NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated

Pdf Summary

The subcohort analysis from the PURPOSE trial investigated the effectiveness of aumolertinib as neoadjuvant therapy for resectable EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). Aumolertinib, a highly effective third-generation EGFR tyrosine kinase inhibitor, has shown promise for postoperative and advanced EGFR-mutated NSCLC. This phase II, open-label, prospective study primarily assessed objective response rates (ORR). Secondary endpoints included pathological complete response (pCR), major pathologic response (MPR), event-free survival (EFS), disease-free survival (DFS), overall survival (OS), complete resection (R0) rate, surgical outcomes estimation, and safety. Exploratory endpoints focused on the predictive value of minimal residual disease (MRD) for treatment efficacy and prognosis.<br /><br />By March 26, 2024, nine patients had completed aumolertinib neoadjuvant therapy followed by radical surgery. The median follow-up was 12 months. Of these patients, six were female and three were male, with eight having lung adenocarcinoma and one having squamous cell carcinoma. Disease staging was stage II in two patients and stage III in seven, with two patients at N1 and seven at N2.<br /><br />Results indicated a 100% ORR and R0 resection rate, with VATS lobectomy performed in 88.9% of cases and open bi-lobectomy in 11.1%. MPR was observed in 33.3% and pCR in 22.2%. Mediastinal lymph node downstaging was achieved in 66.7%. All nine patients achieved successful R0 resections, two attained pCR, and one achieved MPR. MRD detection confirmed negative results post-therapy for all patients previously MRD-positive.<br /><br />The analysis concluded that aumolertinib is effective and feasible for locally advanced EGFR 19del NSCLC, with further results to be disclosed in the future. The study appreciates the efforts of participants, their families, caregivers, and the trial staff.

Asset Subtitle

Wen Fang

Meta Tag

Speaker Wen Fang

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

PURPOSE trial

aumolertinib

neoadjuvant therapy

EGFR-mutated NSCLC

objective response rates

pathological complete response

minimal residual disease

VATS lobectomy

mediastinal lymph node downstaging

locally advanced NSCLC